Prosthetic valve implantation systems

Information

  • Patent Grant
  • 8142492
  • Patent Number
    8,142,492
  • Date Filed
    Wednesday, June 20, 2007
    17 years ago
  • Date Issued
    Tuesday, March 27, 2012
    12 years ago
Abstract
Prosthetic valves implantation methods and systems, especially as related to fitting a prosthetic valve at the site of a native stenotic or incompetent valve are described. The subject devices, systems and associated dock deployment and implant docking techniques may be employed in percutaneous valve replacement procedures.
Description
BACKGROUND OF THE INVENTION

Diseases and other disorders of the heart valves affect the proper flow of blood from the heart. Two categories of heart valve disease are stenosis and incompetence. Stenosis refers to a failure of the valve to open fully, due to stiffened valve tissue. Incompetence refers to valves that cause inefficient blood circulation by permitting backflow of blood in the heart.


Medication may be used to treat some heart valve disorders, but many cases require replacement of the native valve with a prosthetic heart valve. Prosthetic heart valves can be used to replace any of the native heart valves (aortic, mitral, tricuspid or pulmonary), although repair or replacement of the aortic or mitral valves is most common because they reside in the left side of the heart where pressures are the greatest.


Conventional heart valve replacement surgery involves accessing the heart in the patent's thoracic cavity through a longitudinal incision in the chest. For example, a median sternotomy requires cutting through the sternum and forcing the two opposing halves of the rib cage to be spread apart, allowing access to the thoracic cavity and heart within. The patient is then placed on cardiopulmonary bypass support which involves stopping the heart to permit access to the internal chambers. Such open heart surgery is particularly invasive and involves a lengthy and difficult recovery period.


Percutaneous implantation of a prosthetic valve is a preferred procedure because the operation is performed under local anesthesia, may not require cardiopulmonary bypass, and is less traumatic. Various types of prosthetics are adapted for such use. One class employs a stent like outer body and internal valve leaflets attached thereto to provide one way blood flow. These stent structures are radially contracted for delivery to the intended site, and then expanded/deployed to achieve a tubular structure in the annulus. Another more advantageous class is offered by the assignee hereof. US Patent Publication No. 2005/0203614 (hereinafter “the '614 application,” which application is incorporated by reference herein in its entirety) describes a system in which various panels define the implant body carrying valve leaflets. These prosthetic valve structures are delivered in a contracted state and then unfolded and/or unrolled into an expanded state at the treatment location. An example of such a valve is depicted in FIG. 1A. As shown, valve prosthesis 101 is adapted to carry a valve 107 having multiple leaflets 108. The valve support structure 106 includes a plurality of panels 109 that can transition from the state shown to an inverted state as described in the '614 publication.


With either type of structure, a sufficient engagement between patient body tissue and the prosthesis body is desired to secure the position of the implant and form a peripheral seal. However, when implanting the prosthetic device at the site of/within the envelope of the native valve, the condition of the native valve can interfere with fit. Stated otherwise, irregularity in the shape of the implantation site, surface features, texture, and composition pose challenges for developing an implant of a regular size able to accommodate all such variability.


Aspects of the invention optionally address the challenges presented by prosthetic member interface with calcific and/or irregular valve leaflet and annulus geometry. In addition, other advantages of the present invention may be apparent to those with skill in the art upon review of the subject disclosure.


BRIEF SUMMARY OF THE INVENTION

This summary is provided by way of exemplary embodiments. In no way is this summary intended to provide limitation to the scope of the appended claims.


Accordingly, the systems and methods described herein include “docking” type devices for interfacing with replacement prosthetic valves. In some exemplary embodiments, these docking devices are in the form of a sleeve adapted to secure a valve body within a central lumen, and interface with native tissue around its periphery. The docking sleeves can be adapted to provide a seal between the native valve or vessel and the valve body.





BRIEF DESCRIPTION OF THE DRAWINGS

The figures provided herein are not necessarily drawn to scale, with some components and features being exaggerated for clarity. Each of the figures diagrammatically illustrates aspects of the invention. Variation of the invention from the embodiments pictured is contemplated.



FIG. 1A is a perspective view depicting an exemplary valve prosthesis.



FIG. 1B is an illustrative view depicting an exemplary embodiment of a docking system drawing relation to a heart.



FIGS. 2A-C are cross-sectional views depicting an exemplary embodiment of a docking system 100.



FIGS. 3A-B are axial and radial cross-sectional views, respectively, depicting additional exemplary embodiments of docking sleeve.



FIGS. 4A-B are axial cross-sectional and perspective views, respectively, depicting another exemplary embodiment of a docking sleeve.





DETAILED DESCRIPTION OF THE INVENTION

As opposed to known systems, an aspect of the systems and methods described herein contemplates more than a simple docking ring with a limited implant-retention interface. In the systems and methods described herein, the sleeve is adapted to receive at least half, and more typically the entire valve body. Such overlap provides for valve/sleeve interface or securing approaches elaborated upon below. FIG. 1B is a illustrative view depicting a docking system 100 having a support structure 106 of a valve prosthesis 101 as described in the '614 publication and a corresponding docking sleeve 102 adapted to receive valve support structure 106. Placement of the docking sleeve 102 can occur in a location corresponding to the presence of a native valve, such as the aortic valve within the aorta 103 of the heart 104 of a patient.


Another aspect of the systems and methods described herein that distinguish them from known stent-like and simple stent-graft docking structures is that the sleeves described herein offer a space-filling function to provide each of a good interface with irregular anatomy and a central lumen having a regular shape (e.g., circular, oval or elliptical) to accommodate corresponding valve body geometry. Stated otherwise, docking sleeves are provide that adapt to or take-up space and/or compress or expand in sections to provide a superior vessel-side interface while offering an inner lumen with more regular geometry than the implantation site for valve body retention.



FIGS. 2A-C are cross-sectional views depicting an exemplary embodiment of a prosthesis 101 during various stages of deployment within aorta 103. In this embodiment, docking sleeve 102 is configured as a tissue graft with a variable thickness to conform to the underlying vessel anatomy (in this example, within aorta 103). Of course, in other embodiments, docking sleeve 102 can be composed of man-made materials and/or can be configured in a manner that does not enact full conformation with the underlying anatomy. FIG. 2A depicts graft 102 carried on an expandable member (e.g., a balloon) 110 in its unexpanded state disposed on an elongate member (e.g., a catheter shaft) 111. FIG. 2B depicts graft 102 in a deployed configuration against the walls of aorta 103 and filling sinus 112. The deployment of graft 102 is accomplished by inflation of balloon 110. FIG. 2C depicts graft 102 following the removal of balloon 110 and shaft 111 and the deployment of valve structure 106 (leaflets not shown). Here, it can be seen that structure 106 has a lesser length that graft 102, allowing greater freedom in the placement of structure 106. Also, graft 102 provides space-filling conformance with the underlying anatomy.


Such space-filling may be provided by a compliant body or body portion (e.g., biocompatible “spongy” foam such as expanded PTFE deflectable panels or leaf springs for a metallic material such as NiTi, a microporous polymer or metal/metal alloy, etc.), a multi-component/segment or composite body, or a body with a rigid implant-interface lumen and expandable exterior (e.g., as provided by a hydrogel, or permanently inflatable structure—via air, saline or another biocompatible fluid).


For a multi-component sleeve body, inner and outer tubular (e.g., cylindrical) sections may be provided with a spring media provided therebetween. Multiple elastomeric beams or metal spring (coil, torsion, zig-zag, etc.) elements may be employed for such purposes. Alternatively, an air-spring approach with an interposed balloon (distensible or non-distensible) may be utilized. In the latter case, no additional seal element is required between the inner and outer sleeve housings. However, in the former case, one or more baffle structures (e.g. provided by woven fabric/fiber) may be employed to seal the body from inadvertent blood flow or passage/leakage. In order to avoid inadvertently supplying a cavity prone to thrombus formation, multi-piece sleeve bodies will typically be sealed-off at both ends.



FIGS. 3A-B are axial and radial cross-sectional views, respectively, depicting additional exemplary embodiments of docking sleeve 102 having an inner sleeve 114 and an outer sleeve 115. In FIG. 3A, inner sleeve 114 (which can also be valve support structure 106) and outer sleeve 115 are in spaced relation to each other in the deployed configuration with multiple spring elements 117, which are coiled springs in this embodiment, located and exerting force between the outer surface of inner sleeve 114 and the inner surface of outer sleeve 115. Spring elements 118 serve to provide conformance to the underlying anatomy as well as to center inner sleeve 114 with respect to outer sleeve 115. Empty region 116 is configured to receive valve support structure 106 (not shown). Covering 118, which is a flexible fabric in this embodiment, is placed over the gap between sleeves 114 and 115 to seal the region therebetween from blood flow.


In FIG. 3B, docking sleeve 102 is shown in an exemplary intermediate undeployed configuration. Here, sleeves 114 and 115 are in a “tri-star” configuration similar to that described in the incorporated '614 application. Here, device 102 has three segments 123 arranged in a star-like manner. From this configuration, the profile of the device to be reduced further by rolling each segment towards the center axis 124. Sleeves 114 and 115 can be made to enter this configuration by inverting or deflecting each of panels 121 and 122, respectively, towards the center axis 124 of the device in a manner similar to that described in the '614 application. Hinges 119 and 120 are included between panels 121 and 122, respectively, to facilitate transition between the tri-star and deployed configurations. Although spring elements 117 can also be seen, covering 118 is not shown for clarity.


The length of the sleeve may vary as alluded to above. In order to bridge irregular anatomy such as the aortic sinus, the docking sleeve may be elongated relative to the valve body.


In a procedure for implanting a docking sleeve and prosthetic valve according to the present invention, various tissue modification techniques as described in commonly assigned, “Prosthetic Valve Implant Site Preparation Techniques,” provisional application Ser. No. 60/805,333, filed on Jun. 20, 2006 and incorporated by reference in its entirety, can be performed. However, in many instances, the current invention will allow foregoing approach without ill effect.


In one variation of the invention, a method is provided in which the docking sleeve is situated where its implantation is desired during a valvuloplasty procedure. After crossing the native valve leaflets, a balloon is expanded to simultaneously open the leaflets and deploy the docking sleeve.


In order that the interfacing valve is readily available to complete the procedure without compromising patient hemodynamics for an extended period during a beating heart procedure (given that the native valve leaflets are pinned behind the docking sleeve), the valve delivery device may also already be positioned in the aorta for immediate valve body insertion following docking sleeve or station deployment. Such a situation is facilitated by accessing the femoral artery in each leg of a patient to feed the different implant delivery systems (one from the right, and one from the left) into the aortic arch where there is sufficient room to accommodate both.


Alternatively, a temporary valve structure such as described in US Publication No. 2004/0225354 may be provided to allow advancement and delivery of the sleeve, withdrawal of its delivery catheter or guide and substitution for a valve body delivery guide for secondary implant delivery. US Publication No. 2001/0044591 discloses other approaches for percutaneous implant delivery that may alternatively be employed for delivering the docking sleeve and valve body.


As described above, the docking sleeve may be delivered upon a balloon—similar to delivery of a graft. In other variations where the implant comprises a plurality of flexible and/or hinged panels, it may be delivered in a fashion identical to the approach to valve body delivery described directly below.


Specifically, in delivering a prosthetic valve assembly as described in US Publication No. 2005/0203614, after advancing the subject delivery system over the guidewire to the treatment location, its outer sheath is retracted to expose the delivery tube. The gripper provided is then rotated relative to the delivery tube (or the delivery tube rotated relative to the gripper) to cause folded segments of the prosthetic valve to uncurl and to extend radially outward through longitudinal slots of the delivery tube. The delivery tube is then retracted (or the gripper advanced) to cause the prosthetic valve (restrained by the fingers) to advance distally out of the delivery tube. The gripper is then retracted relative to the prosthetic valve, releasing the prosthetic valve into the treatment location. Preferably, the inverted segments then revert to the expanded state, causing the valve to lodge against the internal surface of the body lumen (e.g., the aortic valve root or another biologically acceptable aortic position). Additional expansion of the prosthetic valve may be provided, if needed, by a suitable expansion member, such as an expansion balloon or an expanding mesh member (described elsewhere herein), carried on the delivery catheter or other carrier.


In other methods, different types of prosthetic valves are delivered and deployed within the docking sleeve. In any case, either the valve body or the lumen of the docking sleeve (or both) may be specially adapted to provide a secure interface between the members. Such adaptation may involve complementary VELCRO type hooks, protrusions, tines and loops, dimples, lattice spaces and/or cutouts. Otherwise, a frictional type interface or an interference fit may hold the bodies together. Another means for securing the relative position of the members involves magnets. A plurality of discrete magnetic and/or ferromagnetic elements may be provided. Otherwise, one or both members may be at least partially constructed with magnetic impregnated material (such as polymeric sheet).


Common to all of the approaches, in accordance with another possibly independent aspect of the invention, is the manner in which a large portion or the entirety of the axial length of the implant is engaged with the docking sleeve. The preferred valve body variations have an axial length in which the valve leaflets are set. These “high walls” may help protect the leaflets (especially when closed-wall valve body structures are provided) and offer an advantageous docking member interface in terms of lateral stability as well as providing significant surface area for sturdy frictional, interlocking or other types of engagement between the members. Since the valve body will not be sutured to the docking sleeve (either an inner or outer portion thereof—as applicable) maximizing such contact, while still minimizing device size to aid in deliverability, can be important in providing a secure structure able to handle many millions of cycles of pulsing blood pressure.


Regarding the construction of the docking sleeve, its construction may substantially follow that in the '614 application for its valve bodies. Materials and assembly approaches for providing various “tri-star” and other types of docking sleeves configured as valve bodies presented in the '614 application are specifically contemplated. In some instances, the construction approaches will be modified to provide double-walled, double-cylinder or double-shelled valve docking/retention sleeves as provided herein. With such an endpoint in mind, those with skill in the art can apply the relevant teachings. Generally speaking, the valve body is polymeric, NiTi alloy (where the Af is set for superelastic or SMA use), Beta Titanium alloy, or another suitable biocompatible material or another material with a robust biocompatible coating.


However constructed, it may be desirable to utilize largely closed or uninterrupted sleeve walls to avoid inward migration of native leaflets that can damage the prosthetic leaflets. In other instances, it may be desirable to strategically locate open sections in the sleeve walls to accommodate nested inner and outer portions without overlapping material. Stated otherwise, use of nesting cylinders/shells will avoid overlap resulting in thicker wall sections that can be more difficult to manipulate into a reduce cross-section profile; or stack-up in size making fit within a percutaneous delivery system difficult.


In the latter case, overall valve system patency can be ensured by coordinating the valvular body configuration with the docking sleeve configuration so that holes provided in the outer member of the docking sleeve pair are covered or spanned when the valve body is set in place.



FIGS. 4A-B are axial cross-sectional and perspective views, respectively, depicting another exemplary embodiment of docking sleeve 102 having inner sleeve 114 and outer sleeve 115. FIG. 4A depicts sleeve 102 during deployment. Here, outer sleeve 115 has an aperture 126 configured to receive inner sleeve 114 (which can also be valve support structure 106). Inner sleeve 114 is coupled to outer sleeve 115 by way of a sealing device, which in this embodiment is a fabric 128. Inner sleeve 114 can be positioned within aperture 128 to prevent stack-up of the two sleeves 114 and 115 (i.e., an overlap between the sleeves 114 and 115 that increases the overall wall thickness). FIG. 4B depicts this embodiment while in the tri-star configuration. Fabric 128 is not shown.


In certain methods according to the present invention, the docking sleeve and valve body may be delivered simultaneously. Such an approach avoids the need for temporary valve approaches as described above. In yet another approach, the devices (i.e., the docking sleeve and valve member) are situated in series on a single delivery guide to allow for rapid, sequential deployment utilizing the same delivery device.


In another aspect of the method, the size of each of the prosthetic valve body and docking sleeve may be determined in various ways. Techniques described in U.S. patent application Ser. No. 11/420,189 entitled, “Assessment of Aortic Heart Valve to Facilitate Repair or Replacement,” filed May 24, 2006, may be helpful in this regard. Based on such measurement, appropriately sized docking sleeve and valve bodies may be selected for a given patient from stock or an organized panel of different-sized prostheses.


Various exemplary embodiments of the invention are described below. Reference is made to these examples in a non-limiting sense. They are provided to illustrate more broadly applicable aspects of the invention. Various changes may be made to the invention described and equivalents may be substituted without departing from the true spirit and scope of the invention. In addition, many modifications may be made to adapt a particular situation, material, composition of matter, process, process act(s) or step(s) to the objective(s), spirit or scope of the present invention. Further, as will be appreciated by those with skill in the art that each of the individual variations described and illustrated herein has discrete components and features which may be readily separated from or combined with the features of any of the other several embodiments without departing from the scope or spirit of the present inventions. All such modifications are intended to be within the scope of the appended claims.


Any of the devices described for carrying out the subject methods may be provided in packaged combination for use in executing the method(s). These supply “kits” may further include instructions for use and be packaged in sterile trays or containers as commonly employed for such purposes.


The invention includes methods that may be performed using the subject devices. The methods may all comprise the act of providing such a suitable device. Such provision may be performed by the end user. In other words, the “providing” act merely requires the end user obtain, access, approach, position, set-up, activate, power-up or otherwise act to provide the requisite device in the subject method. Methods recited herein may be carried out in any order of the recited events which is logically possible, as well as in the recited order of events.


Exemplary aspects of the invention, together with details regarding material selection and manufacture have been set forth above. As for other details of the present invention, these may be appreciated in connection with the above-referenced patents and publications as well as generally know or appreciated by those with skill in the art. For example, one with skill in the art will appreciate that a lubricious coating (e.g., hydrophilic polymers such as polyvinylpyrrolidone-based compositions, fluoropolymers such as tetrafluoroethylene, hydrophilic gel or silicones) may be used in connection with the devices, if desired, to facilitate low friction manipulation or advancement to the treatment site. The same may hold true with respect to method-based aspects of the invention in terms of additional acts as commonly or logically employed.


In addition, though the invention has been described in reference to several examples, optionally incorporating various features, the invention is not to be limited to that which is described or indicated as contemplated with respect to each variation of the invention. Various changes may be made to the invention described and equivalents (whether recited herein or not included for the sake of some brevity) may be substituted without departing from the true spirit and scope of the invention. In addition, where a range of values is provided, it is understood that every intervening value, between the upper and lower limit of that range and any other stated or intervening value in that stated range is encompassed within the invention.


Also, it is contemplated that any optional feature of the inventive variations described may be set forth and claimed independently, or in combination with any one or more of the features described herein. Reference to a singular item, includes the possibility that there are plural of the same items present. More specifically, as used herein and in the appended claims, the singular forms “a,” “an,” “said,” and “the” include plural referents unless the specifically stated otherwise. In other words, use of the articles allow for “at least one” of the subject item in the description above as well as the claims below. It is further noted that the claims may be drafted to exclude any optional element. As such, this statement is intended to serve as antecedent basis for use of such exclusive terminology as “solely,” “only” and the like in connection with the recitation of claim elements, or use of a “negative” limitation.


Without the use of such exclusive terminology, the term “comprising” in the claims shall allow for the inclusion of any additional element—irrespective of whether a given number of elements are enumerated in the claim, or the addition of a feature could be regarded as transforming the nature of an element set forth n the claims. Except as specifically defined herein, all technical and scientific terms used herein are to be given as broad a commonly understood meaning as possible while maintaining claim validity.


The breadth of the present invention is not to be limited to the examples provided and/or the subject specification, but rather only by the scope of the claim language.

Claims
  • 1. A medical apparatus, comprising: a prosthetic valve support structure; anda docking sleeve configured to interface with the support structure and configured for implantation within a blood vessel of a patient, wherein the docking sleeve comprises an inner sleeve and an outer sleeve, and wherein the docking sleeve further comprises a spring member coupled between the inner sleeve and the outer sleeve.
  • 2. The medical apparatus of claim 1, wherein the docking sleeve comprises a tissue graft.
  • 3. The medical apparatus of claim 1, further comprising: an elongate member;an expandable member coupled with the elongate member, the expandable member configured to deploy the docking sleeve.
  • 4. The medical apparatus of claim 1, wherein the docking sleeve is configured to transition from an undeployed state suitable for advancement through the vasculature of a patient to a deployed state.
  • 5. The medical apparatus of claim 1, wherein the docking sleeve is compliant.
  • 6. The medical apparatus of claim 1, further comprising a sealing member configured to seal a space between the inner and outer sleeves.
  • 7. The medical apparatus of claim 1, wherein at least one of the inner sleeve and the outer sleeve comprises a plurality of hinges.
  • 8. The medical apparatus of claim 1, wherein at least one of the inner sleeve and the outer sleeve comprises a plurality of deflectable panels.
  • 9. The medical apparatus of claim 1, wherein the outer sleeve comprises an aperture configured to receive the inner sleeve.
  • 10. The medical apparatus of claim 1, wherein the valve support structure and docking sleeve are each configured to transition from an undeployed state suitable for advancement through the vasculature of a patient to a deployed state.
  • 11. The medical apparatus of claim 10, wherein the docking sleeve is configured to transition from a tri-star configuration.
  • 12. The medical apparatus of claim 1, wherein a plurality of spring members couple the outer sleeve with the inner sleeve.
  • 13. A medical apparatus, comprising: a prosthetic valve support structure; anda docking sleeve configured to interface with the support structure and configured for implantation within a blood vessel of a patient, wherein the docking sleeve is coupled to the valve support structure by a plurality of spring members.
  • 14. The medical apparatus of claim 13, wherein the spring members are configured to center the valve support structure.
  • 15. The medical apparatus of claim 13, wherein the docking sleeve is configured to displace the native anatomy.
  • 16. The medical apparatus of claim 13, wherein the docking sleeve is configured to provide a seal with the native anatomy.
  • 17. The medical apparatus of claim 13, wherein the docking sleeve is configured to anchor against the native anatomy.
  • 18. The medical apparatus of claim 13, wherein the docking sleeve comprises a tissue graft.
  • 19. The medical apparatus of claim 13, wherein the docking sleeve has an inner lumen with a regular cross-sectional shape.
  • 20. The medical apparatus of claim 13, further comprising: an elongate member;an expandable member coupled with the elongate member, the expandable member configured to deploy the docking sleeve.
  • 21. The medical apparatus of claim 13, wherein the docking sleeve is configured to transition from an undeployed state suitable for advancement through the vasculature of a patient to a deployed state.
  • 22. The medical apparatus of claim 13, wherein the docking sleeve is compliant.
  • 23. The medical apparatus of claim 13, further comprising a sealing member configured to seal a space between the valve support structure and the docking sleeve.
  • 24. The medical apparatus of claim 13, wherein the valve support structure and docking sleeve are each configured to transition from an undeployed state suitable for advancement through the vasculature of a patient to a deployed state.
  • 25. The medical apparatus of claim 24, wherein the docking sleeve is configured to transition from a tri-star configuration.
PCT Information
Filing Document Filing Date Country Kind 371c Date
PCT/US2007/071689 6/20/2007 WO 00 12/18/2008
Publishing Document Publishing Date Country Kind
WO2007/149933 12/27/2007 WO A
US Referenced Citations (295)
Number Name Date Kind
1376531 Byrnes Jan 1888 A
1314601 McCaskey Sep 1919 A
3579642 Hefferman May 1971 A
3587115 Shiley Jun 1971 A
3657744 Ersek Apr 1972 A
3671979 Moulopoulos Jun 1972 A
3755823 Hancock Sep 1973 A
3867728 Stubstad et al. Feb 1975 A
4056854 Boretos et al. Nov 1977 A
4106129 Carpentier et al. Aug 1978 A
4328839 Lyons et al. May 1982 A
4339831 Johnson Jul 1982 A
4340091 Skelton et al. Jul 1982 A
4624822 Arru et al. Nov 1986 A
4683883 Martin Aug 1987 A
4692165 Bokros Sep 1987 A
4758151 Arru et al. Jul 1988 A
4822345 Danforth Apr 1989 A
4822353 Bokros Apr 1989 A
4856516 Hillstead Aug 1989 A
4878495 Grayzel Nov 1989 A
4878906 Lindemann et al. Nov 1989 A
4960424 Grooters Oct 1990 A
4994077 Dobben Feb 1991 A
5002567 Bona et al. Mar 1991 A
5037434 Lane Aug 1991 A
5078737 Bona et al. Jan 1992 A
5098374 Othel-Jacobsen et al. Mar 1992 A
5123919 Sauter et al. Jun 1992 A
5163953 Vince Nov 1992 A
5163954 Curcio et al. Nov 1992 A
5213580 Slepian et al. May 1993 A
5238454 Schmidt Aug 1993 A
5326371 Love et al. Jul 1994 A
5328471 Slepian Jul 1994 A
5332402 Teitelbaum Jul 1994 A
5370685 Stevens Dec 1994 A
5397348 Campbell et al. Mar 1995 A
5397351 Pavcnik et al. Mar 1995 A
5403305 Sauter et al. Apr 1995 A
5411552 Andersen et al. May 1995 A
5423886 Arru et al. Jun 1995 A
5443474 Sfakianos et al. Aug 1995 A
5454838 Vallana et al. Oct 1995 A
5522885 Love et al. Jun 1996 A
5531094 More et al. Jul 1996 A
5545214 Stevens Aug 1996 A
5554185 Block et al. Sep 1996 A
5560487 Starr Oct 1996 A
5582607 Lackman Dec 1996 A
5607442 Fischell et al. Mar 1997 A
5620456 Sauer et al. Apr 1997 A
5668425 Marioni et al. Sep 1997 A
5695515 Orejola Dec 1997 A
5713860 Kaplan et al. Feb 1998 A
5713953 Vallana et al. Feb 1998 A
5716370 Williamson et al. Feb 1998 A
5724705 Hauser et al. Mar 1998 A
5772672 Toy et al. Jun 1998 A
5814097 Sterman et al. Sep 1998 A
5823342 Caudillo et al. Oct 1998 A
5840081 Andersen et al. Nov 1998 A
5855601 Bessler et al. Jan 1999 A
5868708 Hart et al. Feb 1999 A
5891195 Klostermeyer et al. Apr 1999 A
5919225 Lau et al. Jul 1999 A
5921993 Yoon Jul 1999 A
5925063 Khosravi Jul 1999 A
5957949 Leonhardt et al. Sep 1999 A
5980570 Simpson Nov 1999 A
5984959 Robertson et al. Nov 1999 A
6027779 Campbell et al. Feb 2000 A
6042607 Williamson, IV et al. Mar 2000 A
6051014 Jang Apr 2000 A
6053922 Krause et al. Apr 2000 A
6090138 Chasak et al. Jul 2000 A
6092529 Cox Jul 2000 A
6093530 McIlroy et al. Jul 2000 A
6102944 Huynh et al. Aug 2000 A
6102945 Campbell Aug 2000 A
6117169 Moe Sep 2000 A
6132986 Pathak et al. Oct 2000 A
6143024 Campbell et al. Nov 2000 A
6143025 Stobie et al. Nov 2000 A
6162172 Cosgrove et al. Dec 2000 A
6168614 Andersen et al. Jan 2001 B1
6174331 Moe et al. Jan 2001 B1
6182664 Cosgrove Feb 2001 B1
6197053 Cosgrove et al. Mar 2001 B1
6199696 Lytle et al. Mar 2001 B1
6206918 Campbell et al. Mar 2001 B1
6217610 Carpentier et al. Apr 2001 B1
6231578 Rajhansa May 2001 B1
6231602 Carpentier et al. May 2001 B1
6241765 Griffin et al. Jun 2001 B1
6245102 Jayaraman Jun 2001 B1
6270526 Cox Aug 2001 B1
6283995 Moe et al. Sep 2001 B1
6287339 Vazquez et al. Sep 2001 B1
6299637 Shaolian et al. Oct 2001 B1
6299638 Sauter Oct 2001 B1
6338740 Carpentier Jan 2002 B1
6342070 Nguyen-Thien-Nhon Jan 2002 B1
6348068 Campbell et al. Feb 2002 B1
6350281 Rhee Feb 2002 B1
6350732 Moore et al. Feb 2002 B1
6364905 Simpson et al. Apr 2002 B1
6371983 Lane Apr 2002 B1
6383147 Stobie May 2002 B1
6391054 Carpentier et al. May 2002 B2
6402780 Williamson, IV et al. Jun 2002 B2
6405084 Plicchi et al. Jun 2002 B2
6409758 Stobie et al. Jun 2002 B2
6425916 Garrison et al. Jul 2002 B1
6453062 MacNutt et al. Sep 2002 B1
6454799 Schreck Sep 2002 B1
6458155 Van Nguyen et al. Oct 2002 B1
6461382 Cao Oct 2002 B1
6475239 Campbell et al. Nov 2002 B1
6479079 Pathak et al. Nov 2002 B1
6482228 Norred Nov 2002 B1
6485512 Cheng Nov 2002 B1
6493585 Plicchi et al. Dec 2002 B2
6530952 Vesely Mar 2003 B2
6544279 Hopkins et al. Apr 2003 B1
6558418 Carpentier et al. May 2003 B2
6565602 Rolando et al. May 2003 B2
6569196 Vesely May 2003 B1
6572642 Rinaldi et al. Jun 2003 B2
6582462 Andersen et al. Jun 2003 B1
6585632 Vallana et al. Jul 2003 B2
6585766 Huynh et al. Jul 2003 B1
6596471 Pathak et al. Jul 2003 B2
6602288 Cosgrove et al. Aug 2003 B1
6613085 Anderson et al. Sep 2003 B1
6616690 Rolando et al. Sep 2003 B2
6635085 Caffey et al. Oct 2003 B1
6638303 Campbell Oct 2003 B1
6652578 Bailey et al. Nov 2003 B2
6663667 Dehdashtian et al. Dec 2003 B2
6673109 Cox Jan 2004 B2
6679871 Hahnen Jan 2004 B2
6682543 Barbut et al. Jan 2004 B2
6682558 Tu et al. Jan 2004 B2
6682559 Myers et al. Jan 2004 B2
6689149 Maahs Feb 2004 B2
6692512 Jang Feb 2004 B2
6706033 Martinez et al. Mar 2004 B1
6719787 Cox Apr 2004 B2
6719788 Cox Apr 2004 B2
6719789 Cox Apr 2004 B2
6723122 Yang et al. Apr 2004 B2
6730118 Spenser et al. May 2004 B2
6733513 Boyle et al. May 2004 B2
6733525 Yang et al. May 2004 B2
6736845 Marquez et al. May 2004 B2
6736846 Cox May 2004 B2
6767362 Schreck Jul 2004 B2
6770083 Seguin Aug 2004 B2
6783988 Dinh et al. Aug 2004 B1
6790219 Murphy Sep 2004 B1
6796972 Sinofsky et al. Sep 2004 B1
6797000 Simpson et al. Sep 2004 B2
6805710 Bolling et al. Oct 2004 B2
6821279 Di Emidio Nov 2004 B2
6821297 Snyders Nov 2004 B2
6846324 Stobie Jan 2005 B2
6849088 Dehdashtian et al. Feb 2005 B2
6858039 McCarthy Feb 2005 B2
6875231 Anduiza et al. Apr 2005 B2
6878168 Carpentier et al. Apr 2005 B2
6893460 Spenser et al. May 2005 B2
6896698 Rolando et al. May 2005 B2
6908481 Cribier Jun 2005 B2
6939365 Fogarty et al. Sep 2005 B1
6945997 Huynh et al. Sep 2005 B2
6951571 Srivastava Oct 2005 B1
6962605 Cosgrove et al. Nov 2005 B2
6986775 Morales et al. Jan 2006 B2
6988881 Motsenbocker et al. Jan 2006 B2
6989028 Lashinski et al. Jan 2006 B2
7004176 Lau Feb 2006 B2
7011669 Kimblad Mar 2006 B2
7011681 Vesely Mar 2006 B2
7011682 Lashinski et al. Mar 2006 B2
7014648 Ambrisco et al. Mar 2006 B2
7018406 Seguin et al. Mar 2006 B2
7060092 Kuribayashi et al. Jun 2006 B2
7252682 Seguin Aug 2007 B2
7374571 Pease et al. May 2008 B2
7429270 Baumgartner et al. Sep 2008 B2
7967857 Lane Jun 2011 B2
20010016758 Plicchi et al. Aug 2001 A1
20010018600 Plicchi et al. Aug 2001 A1
20010039450 Pavcnik et al. Nov 2001 A1
20010049541 Plicchi et al. Dec 2001 A1
20020032482 Cox Mar 2002 A1
20020038128 Turovkiy et al. Mar 2002 A1
20020042651 Liddicoat et al. Apr 2002 A1
20020052647 Rolando et al. May 2002 A1
20020055775 Carpentier et al. May 2002 A1
20020058994 Hill et al. May 2002 A1
20020072793 Rolando et al. Jun 2002 A1
20020095173 Mazzocchi et al. Jul 2002 A1
20020099441 Dehdashtian Jul 2002 A1
20020117264 Rinaldi et al. Aug 2002 A1
20020133226 Marquez et al. Sep 2002 A1
20020138138 Yang Sep 2002 A1
20020161431 Stobie et al. Oct 2002 A1
20020163104 Motsenbocker et al. Nov 2002 A1
20020183766 Seguin Dec 2002 A1
20020183831 Rolando et al. Dec 2002 A1
20030009076 Vallana et al. Jan 2003 A1
20030023262 Welch Jan 2003 A1
20030027332 Lafrance et al. Feb 2003 A1
20030033002 Dehdashtian et al. Feb 2003 A1
20030036795 Andersen et al. Feb 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030055495 Pease et al. Mar 2003 A1
20030065356 Tsugita et al. Apr 2003 A1
20030114913 Spenser et al. Jun 2003 A1
20030114917 Holloway et al. Jun 2003 A1
20030130721 Martin et al. Jul 2003 A1
20030153943 Michael et al. Aug 2003 A1
20030153946 Kimblad Aug 2003 A1
20030195613 Curcio et al. Oct 2003 A1
20030212433 Ambrisco et al. Nov 2003 A1
20040015224 Armstrong et al. Jan 2004 A1
20040030382 St. Goar et al. Feb 2004 A1
20040034380 Woolfson et al. Feb 2004 A1
20040049266 Anduiza et al. Mar 2004 A1
20040078074 Anderson et al. Apr 2004 A1
20040092858 Wilson et al. May 2004 A1
20040092989 Wilson et al. May 2004 A1
20040093060 Seguin et al. May 2004 A1
20040093080 Helmus et al. May 2004 A1
20040127979 Wilson et al. Jul 2004 A1
20040148017 Stobie Jul 2004 A1
20040148018 Carpentier et al. Jul 2004 A1
20040153140 Rolando et al. Aug 2004 A1
20040158276 Barbut et al. Aug 2004 A1
20040172124 Vallana et al. Sep 2004 A1
20040186563 Lobbi Sep 2004 A1
20040199245 Lauterjung Oct 2004 A1
20040210304 Seguin et al. Oct 2004 A1
20040225352 Osborne et al. Nov 2004 A1
20040243222 Osborne et al. Dec 2004 A1
20040249433 Freitag Dec 2004 A1
20050027337 Rudko et al. Feb 2005 A1
20050033398 Seguin Feb 2005 A1
20050038497 Neuendorf et al. Feb 2005 A1
20050043760 Fogarty et al. Feb 2005 A1
20050043790 Seguin Feb 2005 A1
20050043792 Solem et al. Feb 2005 A1
20050065594 DiMatteo et al. Mar 2005 A1
20050075584 Cali Apr 2005 A1
20050075712 Biancucci et al. Apr 2005 A1
20050075725 Rowe Apr 2005 A1
20050090888 Hines et al. Apr 2005 A1
20050096734 Majercak et al. May 2005 A1
20050096740 Langberg et al. May 2005 A1
20050137686 Salahieh et al. Jun 2005 A1
20050137687 Salahieh et al. Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137689 Salahieh et al. Jun 2005 A1
20050137690 Salahieh et al. Jun 2005 A1
20050137691 Salahieh et al. Jun 2005 A1
20050137695 Salahieh et al. Jun 2005 A1
20050137696 Salahieh et al. Jun 2005 A1
20050137699 Salahieh et al. Jun 2005 A1
20050137701 Salahieh et al. Jun 2005 A1
20050143809 Salahieh et al. Jun 2005 A1
20050197695 Stacchino et al. Sep 2005 A1
20050203614 Forster et al. Sep 2005 A1
20050203615 Forster et al. Sep 2005 A1
20050203617 Forster et al. Sep 2005 A1
20050228485 Rolando et al. Oct 2005 A1
20050228495 Macoviak Oct 2005 A1
20050267493 Schreck et al. Dec 2005 A1
20050277959 Cosgrove et al. Dec 2005 A1
20060004442 Spenser et al. Jan 2006 A1
20060015179 Bulman-Fleming et al. Jan 2006 A1
20060025787 Morales et al. Feb 2006 A1
20060025854 Lashinski et al. Feb 2006 A1
20060025855 Lashinski et al. Feb 2006 A1
20060052867 Revuelta Mar 2006 A1
20060058871 Zakay et al. Mar 2006 A1
20060069424 Acosta et al. Mar 2006 A1
20060095052 Chambers May 2006 A1
20060122633 To et al. Jun 2006 A1
20060173537 Yang et al. Aug 2006 A1
20060217764 Abbott et al. Sep 2006 A1
20070016286 Herrmann et al. Jan 2007 A1
20070088431 Bourang et al. Apr 2007 A1
20080140172 Carpenter et al. Jun 2008 A1
Foreign Referenced Citations (11)
Number Date Country
WO 9117720 Nov 1991 WO
WO 9933414 Jul 1999 WO
WO 0176510 Oct 2001 WO
WO 03003949 Jan 2003 WO
WO 03047468 Jun 2003 WO
WO 03096932 Nov 2003 WO
WO 03105670 Dec 2003 WO
WO 2005009285 Feb 2005 WO
WO 2005076973 Aug 2005 WO
WO 2005087140 Sep 2005 WO
WO 2006066150 Jun 2006 WO
Related Publications (1)
Number Date Country
20090228098 A1 Sep 2009 US